Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Thyroid Cancer, Papillary 2Adenocarcinoma, Follicular 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 73Nivolumab 27atezolizumab 15Docetaxel 10Cyclophosphamide 10cemiplimab 9Ipilimumab 9Paclitaxel 8Interleukin-2 8Biopsy 7fludarabine 6durvalumab 6avelumab 6Taxes 6Specimen Handling 6epacadostat 5Magnetic Resonance Spectroscopy 5Immune Checkpoint Inhibitors 5Gemcitabine 5Drug Therapy 5Cisplatin 5Carboplatin 5spartalizumab 4Radiotherapy 4Radiosurgery 4Pemetrexed 4Cetuximab 4utomilumab 3trametinib 3poly ICLC 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Rosiglitazone × Head & Neck × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡